Fierce Pharma
MARCH 5, 2024
A trial of Novo Nordisk's Ozempic on diabetes and kidney disease patients found that it reduced the risk of disease progression and death by 24%.
MedCity News
MARCH 5, 2024
One way that we can address this root cause of burnout is by supporting health care workers in using their time most effectively. That involves deploying technologies that make their lives easier.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 5, 2024
Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. | Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Now, following a lawsuit and a protracted back-and-forth with the U.S. regulator, the FDA has crushed Vanda’s bid.
MedCity News
MARCH 5, 2024
Blockbuster Novo Nordisk drug Ozempic now has clinical trial results showing statistically significant reductions in the risk of kidney disease progression. The company said these results support the expansion of the drug’s label to chronic kidney disease.
Fierce Pharma
MARCH 5, 2024
Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as man | Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as many investors had hoped for.
MedCity News
MARCH 5, 2024
Sandoz drugs Jubbonti and Xgeva are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between the two companies.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MARCH 5, 2024
FarmboxRx’s new maternal health program sends members a food box, along with educational content to support them during their pregnancy. This content focuses on a variety of topics, including prenatal and postpartum care visit compliance, postpartum mental health, immunizations and prenatal and postpartum nutrition.
Fierce Pharma
MARCH 5, 2024
With the fortunes of GSK on the rise after much tumult early in the decade, the company has rewarded CEO Emma Walmsley with a significant pay boost. | With the fortunes of GSK on the rise after much tumult early in the decade, the company has rewarded CEO Emma Walmsley with a significant pay boost. Walmsley collected 12.7 million pounds ($16 million) in total pay last year, a 51% increase from her compensation in 2022.
pharmaphorum
MARCH 5, 2024
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.
Fierce Pharma
MARCH 5, 2024
Sumitomo Pharma’s hundeds of layoffs last summer weren't enough for the struggling company to stem the tide as its revenues decline and its
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
MARCH 5, 2024
GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England, Wales and Northern Ireland.
Fierce Pharma
MARCH 5, 2024
Taiwan’s Formosa Pharmaceuticals has gained an FDA approval for a reformulation of a decades-old corticosteroid. | Taiwan’s Formosa Pharmaceuticals has gained an FDA approval for a reformulation of a decades-old corticosteroid. With that, the company's U.S. commercialization partner, Eyenovia, is gearing up for a launch.
MedCity News
MARCH 5, 2024
Today, clinicians have to spend an inordinate and impractical amount of time combing through the EHR just to find the information they need to provide that level of care. All of that back-end administrative work should be the function of technology.
Copyright Clearance Center
MARCH 5, 2024
March 5, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host, “ Publishers, Copyright & AI: Taking Action ” at the 2024 London Book Fair on Tuesday, 12 March, 10:30 – 11:00am GMT in the Tech Theatre. An international panel of executives from leading scholarly publishers, including Claire Harper , Head of Global Rights & Licensing, Sage , and Sarah Fricker , Group Head of Legal, IOP Publishing , will address questions s
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
MARCH 5, 2024
Most health systems aren’t seeing a huge ROI from their AI investments yet. There are three changes that must happen in order for health systems to start seeing a greater ROI when it comes to AI deployments, according to Michael Kalishman, chief venture officer at Virginia-based Sentara Health.
European Pharmaceutical Review
MARCH 5, 2024
BeiGene has appointed Pilar de la Rocha as its new Head of Europe, Global Clinical Operations. The biotech’s new appointment underlines its commitment to advancing clinical development initiatives in the European region. The company highlighted that 35 percent of patients enrolled in its clinical trials are based in Europe. Pilar de la Rocha brings more than two decades of experience in oncology clinical development to the role, according to Beigene.
Pharmaceutical Technology
MARCH 5, 2024
The UK NHS has introduced the new checkpoint inhibitor immunotherapy dostarlimab (Jemperli) for women with advanced endometrial cancer.
European Pharmaceutical Review
MARCH 5, 2024
International participation and trending topics With over 900 exhibitors, analytica 2024 promises an impressive lineup. Both national and international market leaders are represented, with a noticeable increase, particularly from China. Innovative startups and smaller companies show great interest in the fair, which has established itself as a springboard for new developments and products.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
MARCH 5, 2024
The premier boutique healthcare investment conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago
European Pharmaceutical Review
MARCH 5, 2024
The US Food and Drug Administration (FDA) recently highlighted data integrity issues concerning premarket submissions received for medical devices. The agency declared that it has identified an increase in fraudulent and unreliable laboratory testing data within these submissions. It advised manufacturers and study sponsors for these products to “carefully evaluate the third parties they engage to conduct performance testing and to independently verify all testing results before submitting to th
pharmaphorum
MARCH 5, 2024
Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease (CKD) in the FLOW trial.
Copyright Clearance Center
MARCH 5, 2024
According to the latest report from dosdoce.com on audio publishing in Spanish-language markets, production and consumption is soaring.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
MARCH 5, 2024
As healthcare facilities and pharmacies try to recover from one of the most disruptive cyberattacks in US history, reports have emerged that the perpetrators may have received a hefty ransom payment.
Pharmaceutical Commerce
MARCH 5, 2024
The pTau217 antibody helps pinpoint pathological changes related to the disease.
pharmaphorum
MARCH 5, 2024
HHS says all pharma companies affected by Medicare price negotiations have filed counteroffers, trumpeting the milestone as a sign the process is working
PharmaTimes
MARCH 5, 2024
Women with atypical endometrial hyperplasia have an increased risk of developing cancer
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
pharmaphorum
MARCH 5, 2024
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences. These expert panellists will reflect on what ‘Innovation as Strategy’ means to them, offering their perspectives, along with practical advice and real-world examples.
Referral MD
MARCH 5, 2024
As we continue to embrace the digital age, technology has become integral to every aspect of our lives. What is role of technology in healthcare insurance today? Technology’s influence is pervasive, from communication to education, e-commerce travel to healthcare. However, the insurance industry, the backbone of our society, needs to adapt to rapid technological advancements.
pharmaphorum
MARCH 5, 2024
US adults who want to measure their blood glucose levels using a wearable biosensor will soon be able to buy one over-the-counter (OTC) from Dexcom
PharmaTimes
MARCH 5, 2024
The non-invasive tool can also improve patient stratification and monitor disease progression
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
281 
Let's personalize your content